81 results on '"Arcaini, L"'
Search Results
2. A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY.
3. MYC ALTERATIONS IN HIV‐ASSOCIATED B CELL LYMPHOMAS: RESULTS OF "EUROMYC" STUDY (A EUROPEAN RETROSPECTIVE STUDY).
4. Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY.
5. The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas.
6. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)
7. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL.
8. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA.
9. PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
10. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL‐DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL.
11. P984: MUTATIONAL PATTERNS IN PH‐NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
12. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
13. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT.
14. A NON‐INTERVENTIONAL STUDY OF OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (URBAN): IMPACT OF COVID‐19 PANDEMIC ON ENROLLMENT AND SAFETY.
15. Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.
16. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
17. Exposure to obinutuzumab does not affect outcomes of SARS‐CoV‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma.
18. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.
19. MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK.
20. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
21. Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.
22. Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
23. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT.
24. Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before.
25. Deciphering molecular complexity of HCV-associated lymphoproliferation.
26. Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study.
27. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
28. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.
29. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
30. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study.
31. Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
32. Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).
33. B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma.
34. Isolated congenital asplenia: An overlooked cause of thrombocytosis.
35. Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome.
36. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
37. Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
38. Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis.
39. Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
40. Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas.
41. Antiviral prophylaxis for hepatitis B carriers affected by diffuse large B cell lymphoma: a matter of survival.
42. Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies.
43. Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.
44. Direct-acting antiviral agents in lymphoproliferative disorders: more complex than expected.
45. Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib.
46. Circulating endothelial cells in COVID-19.
47. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
48. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
49. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.
50. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.